Patents by Inventor Porunellor A. Mathew

Porunellor A. Mathew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
    Patent number: 7041499
    Abstract: The present invention relates to nucleic acid molecules encoding cell surface receptors on immune cells and the characteristic peptides that comprise these receptors. More specifically, the present invention concerns the use of synthetic and recombinant peptides comprising natural killer (“NK”) cell surface receptors. The synthetic and recombinant peptides are used to generate monoclonal antibodies that bind a specific NK cell surface receptor called CS1. The binding of the monoclonal antibody to the NK cell surface receptor leads to NK cell activation. In a particular embodiments of the present invention, the monoclonal antibodies are utilized in a method that inhibits the growth of tumor cells.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: May 9, 2006
    Assignee: University of North Texas Health Science Center
    Inventors: Porunellor A. Mathew, Kent Boles
  • Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
    Publication number: 20030113332
    Abstract: The present invention relates to nucleic acid molecules encoding cell surface receptors on immune cells and the characteristic peptides that comprise these receptors. More specifically, the present invention concerns the use of synthetic and recombinant peptides comprising natural killer (“NK”) cell surface receptors. The synthetic and recombinant peptides are used to generate monoclonal antibodies that bind a specific NK cell surface receptor called CS1. The binding of the monoclonal antibody to the NK cell surface receptor leads to NK cell activation. In a particular embodiments of the present invention, the monoclonal antibodies are utilized in a method that inhibits the growth of tumor cells.
    Type: Application
    Filed: December 12, 2001
    Publication date: June 19, 2003
    Applicant: University of North Texas Health Science Center at Fort Worth
    Inventors: Porunellor A. Mathew, Kent Boles